EP1157110A4 - Neutrokine-alpha et variant d'epissage de neutrokine-alpha - Google Patents

Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Info

Publication number
EP1157110A4
EP1157110A4 EP00908739A EP00908739A EP1157110A4 EP 1157110 A4 EP1157110 A4 EP 1157110A4 EP 00908739 A EP00908739 A EP 00908739A EP 00908739 A EP00908739 A EP 00908739A EP 1157110 A4 EP1157110 A4 EP 1157110A4
Authority
EP
European Patent Office
Prior art keywords
neutrokine
alpha
splice variant
variant
alpha splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00908739A
Other languages
German (de)
English (en)
Other versions
EP1157110A1 (fr
Inventor
Craig A Rosen
Jian Ni
Reinhard Ebner
Guo-Liang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/255,794 external-priority patent/US6716576B1/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP07012741A priority Critical patent/EP1860190A3/fr
Publication of EP1157110A1 publication Critical patent/EP1157110A1/fr
Publication of EP1157110A4 publication Critical patent/EP1157110A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP00908739A 1999-02-23 2000-02-22 Neutrokine-alpha et variant d'epissage de neutrokine-alpha Withdrawn EP1157110A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07012741A EP1860190A3 (fr) 1999-02-23 2000-02-22 Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US255794 1988-10-11
US09/255,794 US6716576B1 (en) 1996-10-25 1999-02-23 Method of assaying Neutrokine-α mRNA level
US12238899P 1999-03-02 1999-03-02
US122388P 1999-03-02
US12409799P 1999-03-12 1999-03-12
US124097P 1999-03-12
US12659999P 1999-03-26 1999-03-26
US126599P 1999-03-26
US12759899P 1999-04-02 1999-04-02
US127598P 1999-04-02
US13041299P 1999-04-16 1999-04-16
US130412P 1999-04-16
US13069699P 1999-04-23 1999-04-23
US130696P 1999-04-23
US13127899P 1999-04-27 1999-04-27
US131278P 1999-04-27
US13167399P 1999-04-29 1999-04-29
US131673P 1999-04-29
US13678499P 1999-05-28 1999-05-28
US136784P 1999-05-28
US14265999P 1999-07-06 1999-07-06
US142659P 1999-07-06
US14582499P 1999-07-27 1999-07-27
US145824P 1999-07-27
US16723999P 1999-11-24 1999-11-24
US167239P 1999-11-24
US16862499P 1999-12-03 1999-12-03
US168624P 1999-12-03
US17110899P 1999-12-16 1999-12-16
US171108P 1999-12-16
US17162699P 1999-12-23 1999-12-23
US17601500P 2000-01-14 2000-01-14
US176015P 2000-01-14
PCT/US2000/004336 WO2000050597A2 (fr) 1999-02-23 2000-02-22 Neutrokine-alpha et variant d'epissage de neutrokine-alpha
US171626P 2009-04-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07012741A Division EP1860190A3 (fr) 1999-02-23 2000-02-22 Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha

Publications (2)

Publication Number Publication Date
EP1157110A1 EP1157110A1 (fr) 2001-11-28
EP1157110A4 true EP1157110A4 (fr) 2006-05-10

Family

ID=27586018

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07012741A Withdrawn EP1860190A3 (fr) 1999-02-23 2000-02-22 Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha
EP00908739A Withdrawn EP1157110A4 (fr) 1999-02-23 2000-02-22 Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07012741A Withdrawn EP1860190A3 (fr) 1999-02-23 2000-02-22 Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha

Country Status (6)

Country Link
EP (2) EP1860190A3 (fr)
JP (2) JP2003526330A (fr)
AU (2) AU777536B2 (fr)
CA (1) CA2363112A1 (fr)
NZ (2) NZ513290A (fr)
WO (1) WO2000050597A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
WO2000050597A2 (fr) * 1999-02-23 2000-08-31 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (fr) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Polypeptide heterologue de la famille tnf
US6969519B2 (en) 2000-03-10 2005-11-29 Human Genome Sciences, Inc. Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2004537290A (ja) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
CA2520097C (fr) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Recepteurs baff tronques
WO2006083961A2 (fr) * 2005-02-01 2006-08-10 Research Development Foundation Polypeptides ciblés
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
EP3037544A1 (fr) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
CA2667802A1 (fr) * 2006-11-03 2008-05-29 Northwestern University Therapie de la sclerose en plaque
US20110038885A1 (en) * 2007-07-26 2011-02-17 Zheng Xin Dong Chemokine analogs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO2000050597A2 (fr) * 1999-02-23 2000-08-31 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
US6403770B1 (en) * 1996-10-25 2002-06-11 Human Genome Sciences, Inc. Antibodies to neutrokine-alpha

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
AU9315298A (en) * 1997-09-12 1999-03-29 Apotech S.A. Kay - a novel immune system protein
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
US6403770B1 (en) * 1996-10-25 2002-06-11 Human Genome Sciences, Inc. Antibodies to neutrokine-alpha
WO2000050597A2 (fr) * 1999-02-23 2000-08-31 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200053, Derwent World Patents Index; Class B04, AN 2000-572093, XP002331367 *

Also Published As

Publication number Publication date
AU777536B2 (en) 2004-10-21
JP2007277249A (ja) 2007-10-25
EP1860190A2 (fr) 2007-11-28
WO2000050597A2 (fr) 2000-08-31
AU2005200237B2 (en) 2007-11-29
EP1157110A1 (fr) 2001-11-28
NZ513290A (en) 2004-05-28
JP2003526330A (ja) 2003-09-09
EP1860190A3 (fr) 2008-03-12
CA2363112A1 (fr) 2000-08-31
AU3002800A (en) 2000-09-14
AU2005200237A1 (en) 2005-02-17
NZ529555A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
EP1157110A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
EP1309718A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
AU3620600A (en) Skin-marking devices and their use
GB9718901D0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9720585D0 (en) Vaccine
EP1507793A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
GB2350631B (en) Combination whipstock and anchor
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB2352523B (en) Fluid-gauging systems and methods
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
EP1194147A4 (fr) Derives d'arylthiazolidinedione et d'aryloxazolidinedione
TW424891U (en) Holding and fixing structure
NO991348L (no) Oljebr°nnr°r
EP1229913A4 (fr) 1-benzazepines substituees et leurs derives
IL129907A0 (en) Alternative splice variants
GB0021915D0 (en) Creating and managing E-receipts
AU2669201A (en) Taccalonolides and their use
HK1046707A1 (zh) 中性活動(NEUTROKINE)-α與中性活動-α粘接變異
GB9929581D0 (en) Comjpositions and their use
GB2354395B (en) Telephone system and circuitry
GB2389158B (en) Anchorage
GB9916675D0 (en) Enigma-sip and enigma-cell
GB9930708D0 (en) MUS101 and homologues thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010924

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060328

17Q First examination report despatched

Effective date: 20061219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070630

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1046707

Country of ref document: HK